Mostrar el registro sencillo del ítem

Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer

dc.contributor.authorBao Caamaño, Aida*
dc.contributor.authorCosta Fraga, Nicolás*
dc.contributor.authorCayrefourcq, L.*
dc.contributor.authorJácome, M.A.*
dc.contributor.authorRodríguez Casanova, Aitor*
dc.contributor.authorMuinelo Romay, Laura*
dc.contributor.authorLópez-López, R.*
dc.contributor.authorAlix-Panabières, C.*
dc.contributor.authorDíaz Lagares, Ángel *
dc.date.accessioned2025-09-09T11:24:55Z
dc.date.available2025-09-09T11:24:55Z
dc.date.issued2023
dc.identifier.citationBao-Caamano A, Costa-Fraga N, Cayrefourcq L, Jácome MA, Rodriguez-Casanova A, Muinelo-Romay L, et al. Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer. Scientific Reports. 2023;13(1).
dc.identifier.issn2045-2322
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/651014b50058624993e2ce66
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21530
dc.description.abstractCirculating tumor cells (CTCs) and epigenetic alterations are involved in the development of metastasis from solid tumors, such as colorectal cancer (CRC). The aim of this study was to characterize the DNA methylation profile of metastasis-competent CTCs in CRC. The DNA methylome of the human CRC-derived cell line CTC-MCC-41 was analyzed and compared with primary (HT29, Caco2, HCT116, RKO) and metastatic (SW620 and COLO205) CRC cells. The association between methylation and the transcriptional profile of CTC-MCC-41 was also evaluated. Differentially methylated CpGs were validated with pyrosequencing and qMSP. Compared to primary and metastatic CRC cells, the methylation profile of CTC-MCC-41 was globally different and characterized by a slight predominance of hypomethylated CpGs mainly distributed in CpG-poor regions. Promoter CpG islands and shore regions of CTC-MCC-41 displayed a unique methylation profile that was associated with the transcriptional program and relevant cancer pathways, mainly Wnt signaling. The epigenetic regulation of relevant genes in CTC-MCC-41 was validated. This study provides new insights into the epigenomic landscape of metastasis-competent CTCs, revealing biological information for metastasis development, as well as new potential biomarkers and therapeutic targets for CRC patients.
dc.description.sponsorshipThis research was funded by the ISCIII (PI18/00307) and the European Regional Development Fund (FEDER), and by the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. We would like to thank all donors who participated in the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. AB-C is funded by a predoctoral contract PFIS (FI19/00240) from Instituto de Salud Carlos III (ISCIII) co-funded by Fondo Social Europeo (FSE). NC-F is funded by a predoctoral contract from Xunta de Galicia (IN606A-2020/004). AR-C is supported by the Roche-Chus Joint Unit (IN853B 2018/03) funded by Axencia Galega de Innovacion (GAIN), Vicepresidencia Segunda e Conselleria de Economia, Empresa e Innovacion. LM-R is funded by a contract Miguel Servet from ISCIII (CP20/00129). CA-P is supported by funding from the European Union Horizon 2020 Research and Innovation program under the Marie Sklodowska-Curie grant agreement No. 765492, by The National Institute of Cancer (INCa, http://www.e-cancer.fr), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, and the ERA-NET TRANSCAN 2 JTC 2016 PROLIPSY, la Fondation ARC pour la Recherche sur le cancer and les Fonds de dotation AFER pour la recherche medicale. AD-L was funded by a contract Juan Rodes (JR17/00016) from Instituto de Salud Carlos III (ISCIII) and by Servizo Galego de Saude (SERGAS). All authors have read the journal's policy on disclosure of potential conflicts of interest, and have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described research.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshNeoplastic Cells, Circulating*
dc.subject.meshDNA Methylation *
dc.subject.meshCaco-2 Cells *
dc.subject.meshEpigenesis, Genetic*
dc.subject.meshEpigenomics *
dc.subject.meshColonic Neoplasms *
dc.titleEpigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer
dc.typeArtigo
dc.authorsophosBao-Caamano, A.; Costa-Fraga, N.; Cayrefourcq, L.; Jácome, M.A.; Rodriguez-Casanova, A.; Muinelo-Romay, L.; López-López, R.; Alix-Panabières, C.; Díaz-Lagares, A.
dc.identifier.doi10.1038/s41598-023-42037-w
dc.identifier.sophos651014b50058624993e2ce66
dc.issue.number1
dc.journal.titleScientific Reports*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)::Oncoloxía médica
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)::Oncoloxía médica
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)::Oncoloxía médica
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Docencia
dc.relation.projectIDISCIII
dc.relation.projectIDEuropean Regional Development Fund (FEDER)
dc.relation.projectIDInstituto de Salud Carlos III (ISCIII)
dc.relation.projectIDFondo Social Europeo (FSE) [JR17/00016]
dc.relation.projectIDXunta de Galicia
dc.relation.projectIDRoche-Chus Joint Unit - Axencia Galega de Innovacion (GAIN), Vicepresidencia Segunda e Conselleria de Economia, Empresa e Innovacion [PI18/00307, 765492]
dc.relation.projectIDEuropean Union
dc.relation.projectIDNational Institute of Cancer (INCa) [CP20/00129]
dc.relation.projectIDSIRIC Montpellier Cancer Grant INCa_Inserm [FI19/00240]
dc.relation.projectIDERA-NET TRANSCAN 2 JTC 2016 PROLIPSY [IN606A-2020/004]
dc.relation.projectIDla Fondation ARC pour la Recherche sur le cancer
dc.relation.projectIDles Fonds de dotation AFER pour la recherche medicale [IN853B 2018/03]
dc.relation.projectIDServizo Galego de Saude (SERGAS)
dc.relation.projectID[DGOS_12553]
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-023-42037-w
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number13


Ficheros en el ítem

Descargar/
Nombre:
1139.pdf
Tamaño:
1.701Mb
Formato:
PDF
Descripción:
Bao-Caamano A, Costa-Fraga N, Cayrefourcq L, Jácome MA, Rodriguez-Casanova A, ...

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)